JP2010519915A5 - - Google Patents

Download PDF

Info

Publication number
JP2010519915A5
JP2010519915A5 JP2009552038A JP2009552038A JP2010519915A5 JP 2010519915 A5 JP2010519915 A5 JP 2010519915A5 JP 2009552038 A JP2009552038 A JP 2009552038A JP 2009552038 A JP2009552038 A JP 2009552038A JP 2010519915 A5 JP2010519915 A5 JP 2010519915A5
Authority
JP
Japan
Prior art keywords
nucleoside
analog
integer
inosine
cytosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2009552038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010519915A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2008/000473 external-priority patent/WO2008106803A1/en
Publication of JP2010519915A publication Critical patent/JP2010519915A/ja
Publication of JP2010519915A5 publication Critical patent/JP2010519915A5/ja
Abandoned legal-status Critical Current

Links

JP2009552038A 2007-03-07 2008-03-07 二本鎖のロックされた核酸組成物 Abandoned JP2010519915A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90546107P 2007-03-07 2007-03-07
US95027107P 2007-07-17 2007-07-17
PCT/CA2008/000473 WO2008106803A1 (en) 2007-03-07 2008-03-07 Double-stranded locked nucleic acid compositions

Publications (2)

Publication Number Publication Date
JP2010519915A JP2010519915A (ja) 2010-06-10
JP2010519915A5 true JP2010519915A5 (enExample) 2011-10-27

Family

ID=39737757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009552038A Abandoned JP2010519915A (ja) 2007-03-07 2008-03-07 二本鎖のロックされた核酸組成物

Country Status (10)

Country Link
US (1) US20090041809A1 (enExample)
EP (1) EP2125853A1 (enExample)
JP (1) JP2010519915A (enExample)
KR (1) KR20100051041A (enExample)
CN (1) CN101687900A (enExample)
AU (1) AU2008222523A1 (enExample)
BR (1) BRPI0808442A2 (enExample)
CA (1) CA2680060A1 (enExample)
MX (1) MX2009009530A (enExample)
WO (1) WO2008106803A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
US8318482B2 (en) 2008-06-06 2012-11-27 Aurora Algae, Inc. VCP-based vectors for algal cell transformation
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
EP2408482A1 (en) 2009-03-19 2012-01-25 Millipore Corporation Removal of microorganisms from fluid samples using nanofiber filtration media
US20110097418A1 (en) * 2009-05-29 2011-04-28 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US8865468B2 (en) 2009-10-19 2014-10-21 Aurora Algae, Inc. Homologous recombination in an algal nuclear genome
US8809046B2 (en) 2011-04-28 2014-08-19 Aurora Algae, Inc. Algal elongases
US9029137B2 (en) 2009-06-08 2015-05-12 Aurora Algae, Inc. ACP promoter
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
US8709765B2 (en) 2009-07-20 2014-04-29 Aurora Algae, Inc. Manipulation of an alternative respiratory pathway in photo-autotrophs
WO2011041789A1 (en) 2009-10-02 2011-04-07 The Trustees Of Columbia University In The City Of New York Piscine reovirus immunogenic compositions
US8846388B2 (en) * 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
CA2802721C (en) * 2010-06-25 2015-08-18 Idera Pharmaceuticals, Inc. Novel agonists of toll-like receptor 3 and methods of their use
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
SG185659A1 (en) 2010-08-10 2012-12-28 Emd Millipore Corp Method for retrovirus removal
PL2655612T3 (pl) 2010-12-23 2017-12-29 Shell Internationale Research Maatschappij B.V. Czynniki uszkadzające geny produkujące pochodne tłuszczowego acylo-coa
BR112013018074A2 (pt) 2011-01-13 2020-12-01 Variation Biotechnologies, Inc. métodos para a preparação de vesículas e formulações produzidas a partir dessas
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
US8722359B2 (en) 2011-01-21 2014-05-13 Aurora Algae, Inc. Genes for enhanced lipid metabolism for accumulation of lipids
CN105413480B (zh) 2011-04-01 2019-03-29 Emd密理博公司 含有纳米纤维的复合材料结构
MX2013012565A (es) 2011-04-28 2013-11-21 Aurora Algae Inc Desaturasas de algas.
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (en) 2012-01-27 2015-11-04 Variation Biotechnologies Inc METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS
HK1206362A1 (zh) 2012-03-21 2016-01-08 Alios Biopharma, Inc. 硫代氨基磷酸酯核苷酸前藥的固體形式
US9157101B2 (en) * 2012-12-21 2015-10-13 Algenol Biotech LLC Cyanobacterium sp. for production of compounds
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
EP3835419A1 (en) 2013-12-12 2021-06-16 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
KR20190011838A (ko) 2014-06-26 2019-02-07 이엠디 밀리포어 코포레이션 개선된 먼지 포집 능력을 갖는 필터 구조
WO2016061131A1 (en) 2014-10-14 2016-04-21 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
MX2017008289A (es) 2014-12-23 2017-10-02 Algenol Biotech LLC Metodos para aumentar la estabilidad de la produccion de compuestos en celulas huesped microbianas.
KR102206959B1 (ko) 2015-04-17 2021-01-25 이엠디 밀리포어 코포레이션 접선방향 유동 여과 모드에서 작동되는 나노섬유 한외여과막을 사용하여 샘플에서 목적하는 생물학적 물질을 정제하는 방법
WO2016196655A1 (en) 2015-06-03 2016-12-08 The Regents Of The University Of California Cas9 variants and methods of use thereof
US10138489B2 (en) 2016-10-20 2018-11-27 Algenol Biotech LLC Cyanobacterial strains capable of utilizing phosphite
EP3655142B1 (en) 2017-07-21 2026-02-25 Merck Millipore Ltd Non-woven fiber membranes
WO2019066571A2 (ko) 2017-09-28 2019-04-04 연세대학교 산학협력단 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
BR112020022294A2 (pt) * 2018-05-04 2021-02-23 Tollys composição e uso de uma composição
US12275964B2 (en) 2018-08-22 2025-04-15 The Regents Of The University Of California Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
WO2020097445A1 (en) 2018-11-09 2020-05-14 Inari Agriculture, Inc. Rna-guided nucleases and dna binding proteins
MX2021010559A (es) 2019-03-07 2021-12-15 Univ California Polipéptidos efectores de crispr-cas y métodos de uso de estos.
KR102256001B1 (ko) * 2019-07-02 2021-05-26 주식회사 엔에이백신연구소 신규한 리보핵산 및 이를 기반으로 하는 약제학적 조성물
CN114761558B (zh) 2019-07-02 2025-08-01 株式会社Na疫苗研究所 新型核糖核酸和基于其的药物组合物
WO2022036255A1 (en) * 2020-08-14 2022-02-17 Allen Institute Artificial expression constructs for modulating gene expression in striatal neurons
CN117320722A (zh) 2021-04-28 2023-12-29 埃尼奥制药公司 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3692899A (en) * 1969-12-17 1972-09-19 Us Health Education & Welfare Inhibition of transplanted tumor growth by polyinosinic-polycytidylic acid in mice
US3952097A (en) * 1974-09-27 1976-04-20 The United States Of America As Represented By The Department Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4024241A (en) * 1974-09-27 1977-05-17 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
US4349538A (en) * 1979-12-07 1982-09-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nuclease-resistant hydrophilic complex of polyriboinosinic-polyribocytidylic acid
EP1167379A3 (en) * 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7157089B1 (en) * 1996-11-26 2007-01-02 Stressgen Biotechnologies Corporation Immune responses using compositions containing stress proteins
JP3756313B2 (ja) * 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2203843C (en) * 1997-04-28 2013-07-23 Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence Liposome-encapsulated poly iclc
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US6083482A (en) * 1999-05-11 2000-07-04 Icn Pharmaceuticals, Inc. Conformationally locked nucleosides and oligonucleotides
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
WO2003066649A1 (en) * 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
AU2003248791A1 (en) * 2002-07-03 2005-11-09 Oncovir, Inc. Method for preparation of poly-iclc and uses thereof
GB0228540D0 (en) * 2002-12-06 2003-01-15 Glaxo Group Ltd Novel compositions
WO2005004794A2 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
CA2587676A1 (en) * 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US7834064B2 (en) * 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
CA2626977A1 (en) * 2005-10-27 2007-05-03 Rosetta Inpharmatics Llc Nucleic acid amplification using non-random primers
WO2007053696A2 (en) * 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication

Similar Documents

Publication Publication Date Title
JP2010519915A5 (enExample)
AU2023229522B2 (en) Compositions and methods for synthesizing 5'-Capped RNAs
JP6640290B2 (ja) 核酸の非特異的標的の捕捉方法
CN102124020B (zh) 自回避分子识别系统用于dna扩增
AU2008260277B2 (en) N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DE69232816T2 (de) Gesteigerte bildung von triple- und doppelhelices aus oligomeren mit modifizierten pyrimidinen
JP2010525813A5 (enExample)
RU2014130600A (ru) Антисмысловые нуклеиновые кислоты
NZ598943A (en) Hbv antisense inhibitors
JP2012502657A5 (enExample)
JP2011502502A5 (enExample)
JP2019529406A5 (enExample)
ES2300375T3 (es) Composiciones y metodos para la deteccion del virus de la inmunodeficiencia humana 2 (hiv-2).
Kumar et al. Design, synthesis, biophysical and primer extension studies of novel acyclic butyl nucleic acid (BuNA)
JP2019534025A5 (enExample)
WO2010040033A4 (en) Methods and compositions for modulating an immune response with immunogenic oligonucleotides
JP5646455B2 (ja) チクングニヤウイルスを検出するための方法
ES2383947T3 (es) Composiciones, métodos y equipos para la detección de ácidos nucleicos del vih-1 y vih-2
De Bouvere et al. Hexitol nucleic acids (HNA): synthesis and properties
EP4342999B1 (en) Compositions, kits and methods for isolating target polynucleotides
US20060014183A1 (en) Extendable probes
HK40084740A (en) Compositions, kits and methods for isolating target polynucleotides
HK40084740B (en) Compositions, kits and methods for isolating target polynucleotides
ES2349543T3 (es) Composiciones, métodos y equipos para la detección de ácidos nucleicos del vih-1 y vih-2.
HK40080484A (en) Method for synthesizing 5'-capped rnas